EMA backs sev­en ther­a­pies, in­clud­ing Mer­ck­'s Ebo­la vac­cine

The first-ever Ebo­la vac­cine is on the precipice of ap­proval af­ter the Eu­ro­pean Med­i­cine’s Agency (EMA) backed the Mer­ck prod­uct in this week’s ros­ter of rec­om­men­da­tions.

The drug­mak­er $MRK be­gan de­vel­op­ing the vac­cine, chris­tened Erve­bo, dur­ing the West African out­break that oc­curred be­tween 2014 and 2016, killing more than 11,000.

The cur­rent out­break in the De­mo­c­ra­t­ic Re­pub­lic of Con­go (DRC) has shown case fa­tal­i­ty rates of ap­prox­i­mate­ly 67%, the agency es­ti­mat­ed. Ear­li­er this year, the WHO de­clared the out­break — which so far has in­fect­ed more than 3,000 peo­ple — a pub­lic health emer­gency of in­ter­na­tion­al con­cern.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.